Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
Curated scientific studies about autoimmune diseases.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
Phase 3 results announced in February 2026 show that obinutuzumab, an anti-CD20 monoclonal antibody, achieved significantly higher rates of...
Read More — Phase 3 MAJESTY Trial Shows Obinutuzumab Achieves Superior Complete Remission Over Tacrolimus in Primary Membranous Nephropathy »A pivotal clinical trial published in Nature Medicine in January 2026 found that an implantable vagus nerve stimulation device significantly...
Read More — Implantable Vagus Nerve Stimulator Reduces Rheumatoid Arthritis Activity in Pivotal RESET-RA Trial, Published in Nature Medicine »A 2026 retrospective study found that efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, achieved recovery outcomes in Guillain-Barre sy...
Read More — Efgartigimod Shows Comparable Efficacy to IVIG in Guillain-Barre Syndrome with Faster Neurological Recovery »A phase 3 clinical trial found that ianalumab, a novel B-cell targeting agent, significantly extended the time patients with immune thromboc...
Read More — Ianalumab plus Eltrombopag Extends Time to Treatment Failure in Previously Treated Immune Thrombocytopenia: Phase 3 VAYHIT2 Trial »A major phase 3 clinical trial published in the New England Journal of Medicine found that atacicept, a dual BAFF/APRIL inhibitor, reduced p...
Read More — Atacicept Reduces Proteinuria by 46% in Phase 3 IgA Nephropathy Trial, ORIGIN 3 Study Shows »A phase 3 clinical trial published in the New England Journal of Medicine found that icotrokinra, the first oral peptide to selectively bloc...
Read More — First-in-Class Oral IL-23 Receptor Blocker Icotrokinra Achieves 65% Skin Clearance in Phase 3 Psoriasis Trial »A Cell Press review in Trends in Molecular Medicine surveys emerging therapies for anti-NMDA receptor encephalitis, including IL-6 inhibitor...
Read More — New Review Maps Future Treatment Directions for Anti-NMDA Receptor Encephalitis »A landmark Dutch randomized trial published in the New England Journal of Medicine has found that methotrexate, long used as a second-line t...
Read More — PREDMETH Trial: Methotrexate Noninferior to Prednisone as First-Line Therapy for Pulmonary Sarcoidosis »A 2025 review of the rapidly expanding pharmacological landscape for Graves' ophthalmopathy highlights how new biologics, including teprotum...
Read More — Novel Biologics Including FcRn Inhibitors and IGF-1R Blockers Transforming Treatment of Graves' Ophthalmopathy »A phase 1-2 study published in the New England Journal of Medicine found that zimislecel, an allogeneic stem cell-derived islet therapy, res...
Read More — Zimislecel Stem Cell-Derived Islet Therapy Restores Insulin Independence in 83% of Type 1 Diabetes Patients in NEJM Phase 1-2 Trial »A bioprinted, off-the-shelf implantable cell therapy developed by Aspect Biosystems restored natural cortisol production in adrenalectomized...
Read More — Implantable Cell Therapy Restores Natural Cortisol Rhythms in Addison's Disease Animal Research »A longitudinal study from the Lupus Clinic at Sapienza University of Rome followed 201 patients with undifferentiated connective tissue dise...
Read More — Longitudinal Study Reveals Which UCTD Patients Are Most Likely to Evolve to Lupus Under Updated 2019 Classification Criteria »